Pasithea Therapeutics Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pasithea Therapeutics Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $486.6K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $15.1K | Mar 30, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($13.90M) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | ($15.96M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($13.94M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($2.17M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($41.0K) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($14.25M) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | ($15.98M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($12.59M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($4.51M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($41.0K) | Mar 30, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $16.06M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $26.12M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $45.18M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $53.32M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $248.0K | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.28M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $2.72M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $2.68M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.90M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.6K | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $14.78M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $23.40M | Mar 24, 2025 |
| FY2024 | Dec 31, 2022 | $42.50M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $51.42M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $241.4K | Mar 30, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.92M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $16.33M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $33.09M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $52.97M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $243.7K | Mar 30, 2022 |